[HTML][HTML] Everolimus for advanced pancreatic neuroendocrine tumors
…, MH Shah, T Ito, CL Bohas, EM Wolin… - … England Journal of …, 2011 - Mass Medical Soc
Background Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …
[HTML][HTML] Lanreotide in metastatic enteropancreatic neuroendocrine tumors
…, E Sedláčková, G Cadiot, EM Wolin… - … England Journal of …, 2014 - Mass Medical Soc
Background Somatostatin analogues are commonly used to treat symptoms associated with
hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects …
hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects …
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a …
…, RE Winkler, J Klimovsky, D Lebwohl, V Jehl, EM Wolin… - The Lancet, 2011 - thelancet.com
Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR),
has shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. …
has shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. …
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide versus …
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide versus …
[HTML][HTML] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
…, E Sedláčková, G Cadiot, EM Wolin… - Endocrine-related …, 2016 - erc.bioscientifica.com
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged
progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine …
progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine …
Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin …
EM Wolin, B Jarzab, B Eriksson, T Walter… - Drug design …, 2015 - Taylor & Francis
In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release
(pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing …
(pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing …
[HTML][HTML] Phase III prospective randomized comparison trial of depot octreotide plus interferon alfa-2b versus depot octreotide plus bevacizumab in patients with …
…, N LoConte, RR McWilliams, EM Wolin… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Purpose Treatment options for neuroendocrine tumors (NETs) remain limited. This trial
assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α …
assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α …
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor–expressing neuroendocrine tumors: the first US phase 2 …
…, S Zamanian, EM Wolin, M Hamiditabar… - Pancreas, 2014 - journals.lww.com
Objective Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a
novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For …
novel method of treatment in patients with metastatic neuroendocrine tumors (NETs). For …
[HTML][HTML] The expanding role of somatostatin analogs in the management of neuroendocrine tumors
EM Wolin - Gastrointestinal cancer research: GCR, 2012 - ncbi.nlm.nih.gov
BACKGROUND: Neuroendocrine tumors (NETs) are neoplasms arising most often in the GI
tract, pancreas, or lung. Diagnosis of NETs is often delayed until the disease is advanced, …
tract, pancreas, or lung. Diagnosis of NETs is often delayed until the disease is advanced, …
Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled …
…, S Saletan, J Klimovsky, A Panneerselvam, EM Wolin - Chest, 2013 - Elsevier
Background The incidence of neuroendocrine tumors (NETs) has increased approximately
fivefold since the 1980s. A similar increase in the incidence of lung NETs has been reported, …
fivefold since the 1980s. A similar increase in the incidence of lung NETs has been reported, …